Pharmaceutical company AstraZeneca, following the global withdrawal of its Covid-19 vaccine, plans to increase its total revenue to $80 billion by 2030, a 75% increase from $45.8 billion in 2023 “We believe this goal is achievable because of the breadth and scale of our portfolio,” AstraZeneca Chief Financial Officer (CFO) Aradhana Sarin said on “CNBC” on Tuesday. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and is expected to launch an additional 20 drugs over the next six years. “Many of these have the potential to become $5 billion drugs,” Sarin noted. AstraZeneca's plans include developing drugs to treat at least half of all possible cancers and developing alternatives to classic treatments such as chemotherapy and radiation. “To replace the entire market will take time, but we believe we have it today […]
Source: News Beast
With 6 years of experience, I bring to the table captivating and informative writing in the world news category. My expertise covers a range of industries, including tourism, technology, forex and stocks. From brief social media posts to in-depth articles, I am dedicated to creating compelling content for various platforms.
